The University of Chicago Header Logo

Connection

Lucy Godley to Humans

Back to Details
This is a "connection" page, showing publications Lucy Godley has written about Humans.
Lucy Godley
Connection Strength
2.026
Humans
  1. Genetic and environmental risks for clonal hematopoiesis and cancer. J Exp Med. 2025 Jan 06; 222(1).
    View in: PubMed
    Score: 0.032
  2. The impact of next-generation sequencing for diagnosis and disease understanding of myeloid malignancies. Expert Rev Mol Diagn. 2024 Jul; 24(7):591-600.
    View in: PubMed
    Score: 0.031
  3. Germline Predisposition in Hematologic Malignancies: Testing, Management, and Implications. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e432218.
    View in: PubMed
    Score: 0.031
  4. Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants. Gynecol Oncol. 2024 08; 187:235-240.
    View in: PubMed
    Score: 0.031
  5. Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders. Best Pract Res Clin Haematol. 2024 Mar; 37(1):101537.
    View in: PubMed
    Score: 0.030
  6. Germline loss-of-function BRCA1 and BRCA2 mutations and risk of de novo hematopoietic malignancies. Haematologica. 2024 01 01; 109(1):351-356.
    View in: PubMed
    Score: 0.030
  7. Sequential tumor molecular profiling identifies likely germline variants. Genet Med. 2024 03; 26(3):101037.
    View in: PubMed
    Score: 0.030
  8. Germ line risk variants: beyond cancer. Blood. 2023 08 17; 142(7):616-617.
    View in: PubMed
    Score: 0.029
  9. Germline predisposition to clonal hematopoiesis. Leuk Res. 2023 09; 132:107344.
    View in: PubMed
    Score: 0.029
  10. Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood Adv. 2023 05 09; 7(9):1910-1914.
    View in: PubMed
    Score: 0.029
  11. DDX41-associated susceptibility to myeloid neoplasms. Blood. 2023 03 30; 141(13):1544-1552.
    View in: PubMed
    Score: 0.029
  12. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2023 02 28; 7(4):549-554.
    View in: PubMed
    Score: 0.028
  13. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood. 2022 12 15; 140(24):2533-2548.
    View in: PubMed
    Score: 0.028
  14. Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations. Blood Adv. 2022 08 09; 6(15):4357-4359.
    View in: PubMed
    Score: 0.027
  15. MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia. Epigenetics. 2022 12; 17(13):2056-2074.
    View in: PubMed
    Score: 0.027
  16. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies. Curr Hematol Malig Rep. 2022 08; 17(4):94-104.
    View in: PubMed
    Score: 0.027
  17. A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias. Genet Med. 2022 04; 24(4):931-954.
    View in: PubMed
    Score: 0.026
  18. BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines. Haematologica. 2021 12 01; 106(12):3223-3227.
    View in: PubMed
    Score: 0.026
  19. Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology. JCO Precis Oncol. 2021 11; 5:107-122.
    View in: PubMed
    Score: 0.026
  20. Germline predisposition to hematopoietic malignancies. Hum Mol Genet. 2021 10 01; 30(20):R225-R235.
    View in: PubMed
    Score: 0.026
  21. Anticipation in hematopoietic malignancies: biology, bias, or both? Leuk Lymphoma. 2021 12; 62(13):3070-3072.
    View in: PubMed
    Score: 0.026
  22. Germline mutations in MDS/AML predisposition disorders. Curr Opin Hematol. 2021 03 01; 28(2):86-93.
    View in: PubMed
    Score: 0.025
  23. Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities. Br J Haematol. 2021 08; 194(4):663-676.
    View in: PubMed
    Score: 0.024
  24. Identifying potential germline variants from sequencing hematopoietic malignancies. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):219-227.
    View in: PubMed
    Score: 0.024
  25. Identifying potential germline variants from sequencing hematopoietic malignancies. Blood. 2020 11 26; 136(22):2498-2506.
    View in: PubMed
    Score: 0.024
  26. Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies. Blood Adv. 2020 10 27; 4(20):5269-5284.
    View in: PubMed
    Score: 0.024
  27. HIF-1 directly induces TET3 expression to enhance 5-hmC density and induce erythroid gene expression in hypoxia. Blood Adv. 2020 07 14; 4(13):3053-3062.
    View in: PubMed
    Score: 0.024
  28. Inherited predisposition to myeloid malignancies. Blood Adv. 2019 09 10; 3(17):2688.
    View in: PubMed
    Score: 0.022
  29. FouNdER mutations confer risk for leukemias. Blood. 2019 06 20; 133(25):2636-2638.
    View in: PubMed
    Score: 0.022
  30. Somatic mutation panels: Time to clear their names. Cancer Genet. 2019 06; 235-236:84-92.
    View in: PubMed
    Score: 0.022
  31. Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. Curr Hematol Malig Rep. 2018 12; 13(6):426-434.
    View in: PubMed
    Score: 0.021
  32. MBD4: guardian of the epigenetic galaxy. Blood. 2018 10 04; 132(14):1468-1469.
    View in: PubMed
    Score: 0.021
  33. Identifying patients with genetic predisposition to acute myeloid leukemia. Best Pract Res Clin Haematol. 2018 12; 31(4):373-378.
    View in: PubMed
    Score: 0.021
  34. Mutant RUNX1 and histone tales. Blood. 2017 11 16; 130(20):2156-2157.
    View in: PubMed
    Score: 0.020
  35. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017 07 27; 130(4):424-432.
    View in: PubMed
    Score: 0.019
  36. Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017 Aug; 106(2):189-195.
    View in: PubMed
    Score: 0.019
  37. Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biol Blood Marrow Transplant. 2016 11; 22(11):2100-2103.
    View in: PubMed
    Score: 0.018
  38. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016 10 06; 128(14):1800-1813.
    View in: PubMed
    Score: 0.018
  39. TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer. Sci Rep. 2015 Dec 03; 5:17568.
    View in: PubMed
    Score: 0.017
  40. Correspondence Regarding the Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biol Blood Marrow Transplant. 2016 Jan; 22(1):183-4.
    View in: PubMed
    Score: 0.017
  41. Characterization of CpG sites that escape methylation on the inactive human X-chromosome. Epigenetics. 2015; 10(9):810-8.
    View in: PubMed
    Score: 0.017
  42. 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy. Cancer Genet. 2015 May; 208(5):167-77.
    View in: PubMed
    Score: 0.016
  43. New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine. Immunol Rev. 2015 Jan; 263(1):36-49.
    View in: PubMed
    Score: 0.016
  44. Inherited predisposition to acute myeloid leukemia. Semin Hematol. 2014 Oct; 51(4):306-21.
    View in: PubMed
    Score: 0.016
  45. The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia. 2014 Sep; 28(9):1765-73.
    View in: PubMed
    Score: 0.015
  46. TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Rep. 2014 Jun 12; 7(5):1343-1352.
    View in: PubMed
    Score: 0.015
  47. A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma. 2014 Dec; 55(12):2945-6.
    View in: PubMed
    Score: 0.015
  48. On the origin of leukemic species. Cell Stem Cell. 2014 Apr 03; 14(4):421-2.
    View in: PubMed
    Score: 0.015
  49. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol Cancer Ther. 2014 May; 13(5):1334-44.
    View in: PubMed
    Score: 0.015
  50. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep. 2014 Jan 16; 6(1):231-244.
    View in: PubMed
    Score: 0.015
  51. Perspectives and future directions for epigenetics in hematology. Blood. 2013 Jun 27; 121(26):5131-7.
    View in: PubMed
    Score: 0.014
  52. Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. Semin Hematol. 2013 Jan; 50(1):61-9.
    View in: PubMed
    Score: 0.014
  53. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012 Dec 20; 120(26):5247-9.
    View in: PubMed
    Score: 0.014
  54. A drug that stops traffic at the nuclear border. Blood. 2012 Aug 30; 120(9):1759-60.
    View in: PubMed
    Score: 0.014
  55. Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. Cancer Res. 2012 Sep 15; 72(18):4714-23.
    View in: PubMed
    Score: 0.014
  56. Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma. 2013 Jan; 54(1):28-35.
    View in: PubMed
    Score: 0.014
  57. Profiles in leukemia. N Engl J Med. 2012 Mar 22; 366(12):1152-3.
    View in: PubMed
    Score: 0.013
  58. The histone code and treatments for acute myeloid leukemia. N Engl J Med. 2012 Mar 08; 366(10):960-1.
    View in: PubMed
    Score: 0.013
  59. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.
    View in: PubMed
    Score: 0.012
  60. Molecular biology. Preference by exclusion. Science. 2011 Feb 25; 331(6020):1017-8.
    View in: PubMed
    Score: 0.012
  61. Getting to the root of the stem cell in mutated chronic myeloid leukemia. Leuk Lymphoma. 2010 Dec; 51(12):2147-8.
    View in: PubMed
    Score: 0.012
  62. Identification and molecular characterization of a novel 3′ mutation in RUNX1 in a family with familial platelet disorder. Leuk Lymphoma. 2010 Oct; 51(10):1931-5.
    View in: PubMed
    Score: 0.012
  63. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells Mol Dis. 2010 Dec 15; 45(4):317-23.
    View in: PubMed
    Score: 0.012
  64. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res. 2010 Jul 15; 70(14):5840-50.
    View in: PubMed
    Score: 0.012
  65. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006.
    View in: PubMed
    Score: 0.012
  66. The next frontier for stem cell transplantation: finding a donor for all. JAMA. 2010 Apr 14; 303(14):1421-2.
    View in: PubMed
    Score: 0.012
  67. Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues. Leuk Lymphoma. 2009 Jun; 50(6):871-2.
    View in: PubMed
    Score: 0.011
  68. Therapy-related myeloid leukemia. Semin Oncol. 2008 Aug; 35(4):418-29.
    View in: PubMed
    Score: 0.010
  69. The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells. Leuk Lymphoma. 2008 Aug; 49(8):1567-77.
    View in: PubMed
    Score: 0.010
  70. Aberrant RNA splicing and its functional consequences in cancer cells. Dis Model Mech. 2008 Jul-Aug; 1(1):37-42.
    View in: PubMed
    Score: 0.010
  71. HMGA2 levels in CML: reflective of miRNA gene regulation in a hematopoietic tumor? Leuk Lymphoma. 2007 Oct; 48(10):1898-9.
    View in: PubMed
    Score: 0.010
  72. The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma. 2007 Sep; 48(9):1676-95.
    View in: PubMed
    Score: 0.010
  73. Implications of FLT3 mutations in the therapy of acute myeloid leukemia. Rev Recent Clin Trials. 2007 May; 2(2):135-41.
    View in: PubMed
    Score: 0.009
  74. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024 Nov 21; 144(21):2169-2173.
    View in: PubMed
    Score: 0.008
  75. Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders. Clin Cancer Res. 2024 Nov 15; 30(22):5009-5020.
    View in: PubMed
    Score: 0.008
  76. Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition. Blood. 2024 10 24; 144(17):1765-1780.
    View in: PubMed
    Score: 0.008
  77. Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy. Clin Cancer Res. 2024 Oct 01; 30(19):4286-4295.
    View in: PubMed
    Score: 0.008
  78. Evaluation of the genetic basis of familial-associated early-onset hematologic cancers in an ancestral/ethnically diverse population. Haematologica. 2024 07 01; 109(7):2085-2091.
    View in: PubMed
    Score: 0.008
  79. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.008
  80. Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene-Environment Interactions. Cancer Discov. 2024 Mar 01; 14(3):396-405.
    View in: PubMed
    Score: 0.008
  81. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2024 Mar; 30(3):255-267.
    View in: PubMed
    Score: 0.007
  82. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023 Dec; 10(12):e994-e1005.
    View in: PubMed
    Score: 0.007
  83. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood Adv. 2023 10 24; 7(20):6092-6107.
    View in: PubMed
    Score: 0.007
  84. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
    View in: PubMed
    Score: 0.007
  85. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers. Cancer Discov. 2023 06 02; 13(6):1478-1497.
    View in: PubMed
    Score: 0.007
  86. Pathogenic human variant that dislocates GATA2 zinc fingers disrupts hematopoietic gene expression and signaling networks. J Clin Invest. 2023 04 03; 133(7).
    View in: PubMed
    Score: 0.007
  87. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023 02 02; 141(5):534-549.
    View in: PubMed
    Score: 0.007
  88. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
    View in: PubMed
    Score: 0.007
  89. Classification of rare pediatric myeloid neoplasia-Quo vadis? Leukemia. 2022 12; 36(12):2947-2948.
    View in: PubMed
    Score: 0.007
  90. Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia. Leukemia. 2022 12; 36(12):2827-2834.
    View in: PubMed
    Score: 0.007
  91. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 09 22; 140(12):1345-1377.
    View in: PubMed
    Score: 0.007
  92. Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation. Nat Genet. 2022 10; 54(10):1514-1526.
    View in: PubMed
    Score: 0.007
  93. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
    View in: PubMed
    Score: 0.007
  94. Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Hum Mutat. 2022 07; 43(7):950-962.
    View in: PubMed
    Score: 0.007
  95. The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. 2021 11 01; 106(11):3004-3007.
    View in: PubMed
    Score: 0.006
  96. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021 10 26; 5(20):4140-4148.
    View in: PubMed
    Score: 0.006
  97. Increased burden of familial-associated early-onset cancer risk among minority Americans compared to non-Latino Whites. Elife. 2021 06 22; 10.
    View in: PubMed
    Score: 0.006
  98. Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. Am J Hematol. 2021 09 01; 96(9):E327-E330.
    View in: PubMed
    Score: 0.006
  99. Study of inherited thrombocytopenia resulting from mutations in ETV6 or RUNX1 using a human pluripotent stem cell model. Stem Cell Reports. 2021 06 08; 16(6):1458-1467.
    View in: PubMed
    Score: 0.006
  100. RBL2 bi-allelic truncating variants cause severe motor and cognitive impairment without evidence for abnormalities in DNA methylation or telomeric function. J Hum Genet. 2021 Nov; 66(11):1101-1112.
    View in: PubMed
    Score: 0.006
  101. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. 2021 11; 35(11):3245-3256.
    View in: PubMed
    Score: 0.006
  102. Germline variants drive myelodysplastic syndrome in young adults. Leukemia. 2021 08; 35(8):2439-2444.
    View in: PubMed
    Score: 0.006
  103. Regulation of telomeric function by DNA methylation differs between humans and mice. Hum Mol Genet. 2020 11 25; 29(19):3197-3210.
    View in: PubMed
    Score: 0.006
  104. Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. Genet Med. 2021 01; 23(1):211-214.
    View in: PubMed
    Score: 0.006
  105. Breaking the spatial constraint between neighboring zinc fingers: a new germline mutation in GATA2 deficiency syndrome. Leukemia. 2021 01; 35(1):264-268.
    View in: PubMed
    Score: 0.006
  106. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv. 2020 03 24; 4(6):1131-1144.
    View in: PubMed
    Score: 0.006
  107. How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for RUNX1 variant curation for germline predisposition to myeloid malignancies. Haematologica. 2020 04; 105(4):870-887.
    View in: PubMed
    Score: 0.006
  108. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606.
    View in: PubMed
    Score: 0.006
  109. MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell Chem Biol. 2020 05 21; 27(5):538-550.e7.
    View in: PubMed
    Score: 0.006
  110. Inherited Thrombocytopenia Caused by Germline ANKRD26 Mutation Should Be Considered in Young Patients With Suspected Myelodysplastic Syndrome. J Investig Med High Impact Case Rep. 2020 Jan-Dec; 8:2324709620938941.
    View in: PubMed
    Score: 0.006
  111. 5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. Clin Cancer Res. 2020 03 15; 26(6):1309-1317.
    View in: PubMed
    Score: 0.006
  112. Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis. Leuk Lymphoma. 2020 01; 61(1):246-247.
    View in: PubMed
    Score: 0.006
  113. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. Blood Adv. 2019 10 22; 3(20):2962-2979.
    View in: PubMed
    Score: 0.006
  114. TTID: A novel gene at 5q31 encoding a protein with titin-like features. Genomics. 1999 Sep 01; 60(2):226-33.
    View in: PubMed
    Score: 0.006
  115. Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discov. 2019 06; 9(6):778-795.
    View in: PubMed
    Score: 0.005
  116. Treatment of Acute Promyelocytic Leukemia in Adults. J Oncol Pract. 2018 11; 14(11):649-657.
    View in: PubMed
    Score: 0.005
  117. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019 03; 60(3):629-638.
    View in: PubMed
    Score: 0.005
  118. Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res. 2018 05 15; 78(10):2747-2759.
    View in: PubMed
    Score: 0.005
  119. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2018 01 23; 2(2):146-150.
    View in: PubMed
    Score: 0.005
  120. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4.
    View in: PubMed
    Score: 0.005
  121. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
    View in: PubMed
    Score: 0.005
  122. Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. Genome Res. 2017 11; 27(11):1830-1842.
    View in: PubMed
    Score: 0.005
  123. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017 08 24; 17(9):513-527.
    View in: PubMed
    Score: 0.005
  124. Recognition of familial myeloid neoplasia in adults. Semin Hematol. 2017 04; 54(2):60-68.
    View in: PubMed
    Score: 0.005
  125. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.
    View in: PubMed
    Score: 0.005
  126. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia. 2017 05; 31(5):1226-1229.
    View in: PubMed
    Score: 0.005
  127. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget. 2016 Nov 22; 7(47):76816-76826.
    View in: PubMed
    Score: 0.005
  128. Genetic predisposition to leukemia and other hematologic malignancies. Semin Oncol. 2016 Oct; 43(5):598-608.
    View in: PubMed
    Score: 0.005
  129. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):417-428.e2.
    View in: PubMed
    Score: 0.004
  130. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr; 17(4):496-508.
    View in: PubMed
    Score: 0.004
  131. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072.
    View in: PubMed
    Score: 0.004
  132. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.
    View in: PubMed
    Score: 0.004
  133. Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. Blood. 2016 Mar 24; 127(12):1575-86.
    View in: PubMed
    Score: 0.004
  134. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood. 2016 Feb 25; 127(8):1017-23.
    View in: PubMed
    Score: 0.004
  135. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leuk Lymphoma. 2016 08; 57(8):1807-13.
    View in: PubMed
    Score: 0.004
  136. Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. J Biol Chem. 2016 Feb 19; 291(8):4256-65.
    View in: PubMed
    Score: 0.004
  137. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
    View in: PubMed
    Score: 0.004
  138. Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice. Blood. 2016 Jan 21; 127(3):310-3.
    View in: PubMed
    Score: 0.004
  139. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015 Nov 26; 126(22):2484-90.
    View in: PubMed
    Score: 0.004
  140. DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell Rep. 2015 Sep 29; 12(12):2086-98.
    View in: PubMed
    Score: 0.004
  141. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Res. 2015 Jul 15; 75(14):2833-43.
    View in: PubMed
    Score: 0.004
  142. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell. 2015 May 11; 27(5):658-70.
    View in: PubMed
    Score: 0.004
  143. Node-pore sensing enables label-free surface-marker profiling of single cells. Anal Chem. 2015 Mar 03; 87(5):2988-95.
    View in: PubMed
    Score: 0.004
  144. DNMT3B7 expression promotes tumor progression to a more aggressive phenotype in breast cancer cells. PLoS One. 2015; 10(1):e0117310.
    View in: PubMed
    Score: 0.004
  145. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015 Feb; 47(2):180-5.
    View in: PubMed
    Score: 0.004
  146. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
    View in: PubMed
    Score: 0.004
  147. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014 Dec 11; 9(5):1841-1855.
    View in: PubMed
    Score: 0.004
  148. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014 Oct 10; 32(29):3264-74.
    View in: PubMed
    Score: 0.004
  149. Linking the genetic architecture of cytosine modifications with human complex traits. Hum Mol Genet. 2014 Nov 15; 23(22):5893-905.
    View in: PubMed
    Score: 0.004
  150. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9.
    View in: PubMed
    Score: 0.004
  151. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci. 2014 Mar; 1310:111-8.
    View in: PubMed
    Score: 0.004
  152. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 2014 Mar 13; 123(11):1699-708.
    View in: PubMed
    Score: 0.004
  153. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet. 2014 Jan; 46(1):17-23.
    View in: PubMed
    Score: 0.004
  154. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 2013 Sep; 3(9):1002-19.
    View in: PubMed
    Score: 0.004
  155. Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Nucleic Acids Res. 2013 Sep; 41(16):e157.
    View in: PubMed
    Score: 0.004
  156. Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits. Genetics. 2013 Aug; 194(4):987-96.
    View in: PubMed
    Score: 0.004
  157. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplant. 2013 Nov; 48(11):1437-43.
    View in: PubMed
    Score: 0.004
  158. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53.
    View in: PubMed
    Score: 0.004
  159. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells. Anticancer Drugs. 2013 Jun; 24(5):484-93.
    View in: PubMed
    Score: 0.004
  160. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013 Jun; 54(6):1242-9.
    View in: PubMed
    Score: 0.004
  161. High resolution methylome analysis reveals widespread functional hypomethylation during adult human erythropoiesis. J Biol Chem. 2013 Mar 29; 288(13):8805-14.
    View in: PubMed
    Score: 0.004
  162. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012 Nov; 44(11):1179-81.
    View in: PubMed
    Score: 0.003
  163. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leuk Lymphoma. 2013 Feb; 54(2):408-10.
    View in: PubMed
    Score: 0.003
  164. Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy. 2012 Jul; 14(6):707-15.
    View in: PubMed
    Score: 0.003
  165. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.003
  166. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 2012 Feb; 7(2):201-7.
    View in: PubMed
    Score: 0.003
  167. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. Int J Gynecol Pathol. 2012 Jan; 31(1):15-24.
    View in: PubMed
    Score: 0.003
  168. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011 Dec 04; 44(1):23-31.
    View in: PubMed
    Score: 0.003
  169. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.
    View in: PubMed
    Score: 0.003
  170. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci. 2011 Oct 30; 14(12):1607-16.
    View in: PubMed
    Score: 0.003
  171. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45.
    View in: PubMed
    Score: 0.003
  172. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 2011 Sep 29; 118(13):3559-69.
    View in: PubMed
    Score: 0.003
  173. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood. 2011 Sep 01; 118(9):2551-5.
    View in: PubMed
    Score: 0.003
  174. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011 Jul 12; 20(1):11-24.
    View in: PubMed
    Score: 0.003
  175. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011 Jul 12; 20(1):25-38.
    View in: PubMed
    Score: 0.003
  176. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
    View in: PubMed
    Score: 0.003
  177. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res. 2011 Apr 15; 17(8):2170-80.
    View in: PubMed
    Score: 0.003
  178. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24; 117(12):3294-301.
    View in: PubMed
    Score: 0.003
  179. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol. 2011 Jan; 29(1):68-72.
    View in: PubMed
    Score: 0.003
  180. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011 Feb; 52(2):214-22.
    View in: PubMed
    Score: 0.003
  181. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec 14; 18(6):553-67.
    View in: PubMed
    Score: 0.003
  182. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.
    View in: PubMed
    Score: 0.003
  183. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer. 2010 Jun 14; 10:286.
    View in: PubMed
    Score: 0.003
  184. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
    View in: PubMed
    Score: 0.003
  185. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10; 27(23):3842-8.
    View in: PubMed
    Score: 0.003
  186. High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma. Biochem Biophys Res Commun. 2009 Jul 24; 385(2):160-4.
    View in: PubMed
    Score: 0.003
  187. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
    View in: PubMed
    Score: 0.003
  188. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16.
    View in: PubMed
    Score: 0.003
  189. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
    View in: PubMed
    Score: 0.003
  190. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008 Apr 15; 14(8):2444-9.
    View in: PubMed
    Score: 0.003
  191. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma. 2008 Mar; 49(3):531-7.
    View in: PubMed
    Score: 0.003
  192. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
    View in: PubMed
    Score: 0.002
  193. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma. 2007 Sep; 48(9):1799-805.
    View in: PubMed
    Score: 0.002
  194. Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene. 2007 Aug 16; 26(38):5553-63.
    View in: PubMed
    Score: 0.002
  195. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64.
    View in: PubMed
    Score: 0.002
  196. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006 Feb; 37(3):307-10.
    View in: PubMed
    Score: 0.002
  197. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.002
  198. Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):14925-30.
    View in: PubMed
    Score: 0.002
  199. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics. 2001 Jan 15; 71(2):235-45.
    View in: PubMed
    Score: 0.002
  200. cDNA cloning and genomic structure of three genes localized to human chromosome band 5q31 encoding potential nuclear proteins. Genomics. 2000 Nov 15; 70(1):123-30.
    View in: PubMed
    Score: 0.002
  201. Molecular characterization of KLHL3, a human homologue of the Drosophila kelch gene. Genomics. 2000 May 15; 66(1):65-75.
    View in: PubMed
    Score: 0.001
  202. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol Cell Biol. 1996 Jul; 16(7):3765-72.
    View in: PubMed
    Score: 0.001
  203. Defining the steps in a multistep mouse model for mammary carcinogenesis. Cold Spring Harb Symp Quant Biol. 1994; 59:491-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.